Pan-TEAD and MEK inhibitor combination shows strong synergy in head and neck tumors
Nov. 15, 2024
Genetic alterations in FAT1, YAP1 or WWTR1 genes are commonly seen in head and neck squamous cell carcinoma (HNSCC) patients. Targeting Hippo and MAPK pathways in combination has proven effective in preclinical models of HNSCC.